Table 1.
The relationship between the expression of TFEB and clinicopathological variables in BC patients.
| Patients Characteristics | Total |
mRNA expression |
||
|---|---|---|---|---|
| Low(n = 34) | High(n = 34) | P value* | ||
| Age | ||||
| ＜60 | 29 | 14 | 15 | 0.806 |
| ≥60 | 39 | 20 | 19 | |
| TNM stage | ||||
| Ⅰ and Ⅱ | 37 | 12 | 25 | 0.002** |
| Ⅲ and Ⅳ | 31 | 22 | 9 | |
| Tumor size(cm) | ||||
| ≤2 | 36 | 9 | 27 | 0.001*** |
| ＞2 | 32 | 25 | 7 | |
| Lymph node metastasis | 0.595 | |||
| negative | 48 | 23 | 25 | |
| positive | 20 | 11 | 9 | |
| Distant metastasis | 0.283 | |||
| No | 59 | 28 | 31 | |
| Yes | 9 | 6 | 3 | |
The relationships between TFEB expression and patents’ clinicopathologic characteristics were analyzed via Chi-square test or Fisher’s exact test. * p＜0.05, **p0.01,***p < 0.001.